Immuron Limited has published the transcript of its CEO’s presentation at the Emerging Growth Conference, held virtually on January 22, 2026. The event featured Immuron’s Chief Executive Officer, Steven Lydeamore, who addressed investors and stakeholders about the company’s latest advancements. During the call, the CEO highlighted Immuron’s proprietary technology, which utilizes polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum to target infectious diseases. “Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by digestive enzymes,” stated the CEO, emphasizing the unique benefits of the company’s orally active antibody therapies. Key developments discussed included the progress of IMM-124E (Travelan®), designed to combat enterotoxigenic Escherichia coli $(ETEC)$, and ongoing collaborations with Monash University to develop IMM-529 for targeting Clostridioides difficile. The CEO noted, “This unique 3-target approach has yielded promising results in pre-clinical infection and relapse models,” referring to the significant protective and therapeutic outcomes seen with IMM-529. The full transcript can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-006895), on January 23, 2026, and is solely responsible for the information contained therein.